<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Viaskin on Food Allergy Informer</title><link>https://foodallergyinformer.com/tags/viaskin/</link><description>Recent content in Viaskin on Food Allergy Informer</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Sat, 22 Aug 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://foodallergyinformer.com/tags/viaskin/index.xml" rel="self" type="application/rss+xml"/><item><title>The Next Wave of Peanut Allergy Treatments: Pills, Patches, and Tablets</title><link>https://foodallergyinformer.com/blog/peanut-allergy-treatments-in-the-pipeline/</link><pubDate>Sat, 22 Aug 2026 00:00:00 +0000</pubDate><guid>https://foodallergyinformer.com/blog/peanut-allergy-treatments-in-the-pipeline/</guid><description>&lt;p>I wrote a &lt;a href="https://foodallergyinformer.com/blog/peanut-allergy-treatment-oit-and-beyond/">guide to current peanut allergy treatments&lt;/a>
earlier this year covering OIT and Xolair — the tools allergists can actually prescribe today.
But the research pipeline has been moving fast, and 2026 has delivered some genuinely exciting
clinical trial results. For the first time, it feels like we might be looking at a future where
treating a peanut allergy doesn&amp;rsquo;t necessarily mean daily doses of the thing you&amp;rsquo;re allergic to.&lt;/p></description></item></channel></rss>